Roger Medel compensation by year
Pediatrix Medical Summary Compensation Table · all 5 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
| Salary | $1,000,000 | $1,000,000 | $1,000,000 | $500,001 | $1 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $6,150,035 | $6,150,000 | $8,000,040 | $6,150,034 | $6,150,001 |
| Option awards | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $444,000 | $0 | $669,000 | $1,125,000 | $780,822 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $230,750 | $215,508 | $268,977 | $291,241 | $666,430 |
| Total | $7,824,785 | $7,365,508 | $9,938,017 | $8,066,276 | $7,597,254 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Pediatrix Medical Group, Inc. DEF 14A filed March 23, 2021, accession 0001193125-21-091206, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Pediatrix Medical Group, Inc. filed document, accession 0001193125-21-091206. Every figure is read from that document and cited to the page and table it appears in. Filed March 23, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 227,525 | $5,583,464 | — |
| PSU | 118,944 | $2,918,886 | — |
| PSU | 49,146 | $1,206,043 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Pediatrix Medical Group, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.
Pediatrix Medical’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Roger Medel · this page | Former Chief Executive Officer | $7,597,254 |
| Stephen Farber | Former Executive Vice President and Chief Financial Officer | $7,043,175 |
| Mark Ordan | Chief Executive Officer | $6,438,682 |
| Dominic Andreano | Executive Vice President, General Counsel and Secretary | $3,376,947 |
| Roger Hinson | President, Pediatrix and Obstetrix Medical Group | $2,913,219 |
| Nicholas Nikolopoulos | Former Executive Vice President and Chief Strategy & Growth Officer | $2,580,427 |
| C. Marc Richards | Executive Vice President and Chief Financial Officer | $1,967,008 |
| John Pepia | Senior Vice President and Chief Accounting Officer | $1,299,406 |
Board service
Pediatrix Medical board · FY2021–FY2023| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $14,667 | $0 | — | — | $14,667 |
| FY2022 | $80,000 | $150,011 | — | — | $230,011 |
| FY2021 | $50,989 | $150,018 | — | — | $201,007 |
Each year as the company reported it in Pediatrix Medical's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Pediatrix Medical pays directors a $80,000 cash retainer and $150,000 in RSUs. As stated in Pediatrix Medical's FY2023 proxy.
The full Pediatrix Medical compensation record
free company briefThis page is one person within Pediatrix Medical's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Pediatrix Medical proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Pediatrix Medical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.